Zydus receives final approval from the USFDA for Aripiprazole Tablets

Deepthi | Myequity news | Date : 08-01-2019 12:45:00 IST

Zydus Cadila has received the final approval from the USFDA to market Aripiprazole Tablets USP (US RLD - Abilify) in the strengths of 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg. It will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad.

Aripiprazole is an antipsychotic drug (atypical type). It is used to treat mental/mood disorders such as bipolar disorder, schizophrenia, Tourette's disorder, and irritability associated with autistic disorder. It is also used in combination with other medications to treat depression. It works by helping to restore the balance of certain natural chemicals in the brain (neurotransmitters).

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

More from Myequity